Form 4: Virios Therapeutics Director Richard Alan Burch Acquires Stock Options
SEC Form 4 Filing
Director Richard Alan Burch acquired stock options in Virios Therapeutics, Inc. on February 26, 2024.
Summary
- Richard Alan Burch, a director of Virios Therapeutics, Inc., acquired 2,917 stock options on February 26, 2024.
- The options have an exercise price of $0.357.
- The options vest 100% on February 26, 2025, and expire on February 26, 2034.
- Following the transaction, Burch directly owns 2,917 derivative securities.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard insider transaction filing. The acquisition of options could be interpreted as a slightly positive signal, but it's not definitive.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence from a company director.
Key Dates
| Date | Description |
|---|---|
| 02/26/2024 | Date of transaction: Richard Alan Burch acquired stock options. |
| 02/26/2025 | Stock options vest 100%. |
| 02/26/2034 | Stock options expire. |
| 02/28/2024 | Date of signature on the Form 4 filing. |
Keywords
stock options, Form 4, Virios Therapeutics, insider trading, director, VIRI, Richard Alan Burch
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.